XFOR - X4 Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

X4 Pharmaceuticals, Inc.

955 Massachusetts Avenue
4th Floor
Cambridge, MA 02139
United States
857-529-8300
http://www.x4pharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Paula RaganFounder, CEO, Pres, Sec. & DirectorN/AN/A1971
Dr. Renato T. Skerlj Ph.D.Founder and Member of Scientific Advisory BoardN/AN/AN/A
Mr. Adam S. MostafaCFO, Treasurer & Assistant Sec.N/AN/A1980
Ms. Ronny MosstonVP of HRN/AN/AN/A
Dr. Robert David Arbeit M.D.Sr. VP of Clinical Devel. and Translational ResearchN/AN/A1948
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

X4 Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.